GLPG VS BHC Stock Comparison
Performance
GLPG75/100
75/100
GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.
BHC10/100
10/100
BHC returned -4.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
GLPG78/100
78/100
8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.
BHC
"Analyst Price Targets" not found for BHC
Technicals
GLPG71/100
71/100
GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
BHC11/100
11/100
BHC receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
GLPG10/100
10/100
GLPG has missed earnings 10 times in the last 20 quarters.
BHC10/100
10/100
BHC has missed earnings 6 times in the last 20 quarters.
Profit
GLPG40/100
40/100
Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.
BHC32/100
32/100
Out of the last 20 quarters, BHC has had 5 profitable quarters and has increased their profits year over year on 5 of them.
Volatility
GLPG50/100
50/100
GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
BHC50/100
50/100
BHC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Galapagos NV Summary
Nasdaq / GLPG
Healthcare
Biotechnology
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Bausch Health Companies Inc. Summary
New York Stock Exchange / BHC
Healthcare
Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare GLPG to other companies in the same or a similar industry.